Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Lynda J Krasenbaum"'
Autor:
Hsiangkuo Yuan, Fred Cohen, Maurice T Driessen, Lynda J Krasenbaum, Mario Ortega, Mary Hopkins, Michael J Marmura
Publikováno v:
Cephalalgia Reports, Vol 7 (2024)
Background: Concomitant fremanezumab, a calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb), and onabotulinumtoxinA (onabotA) improve treatment response compared with onabotA alone in patients with chronic migraine (CM). Methods:
Externí odkaz:
https://doaj.org/article/bc79059de0f142e58d6ef24009062785
Autor:
Lynda J. Krasenbaum, Vasantha L. Pedarla, Stephen F. Thompson, Krishna Tangirala, Joshua M. Cohen, Maurice T. Driessen
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background Following approval of fremanezumab for the prevention of migraine in adults, health care decision makers are interested in understanding real-world clinical characteristics and treatment patterns among patients initiating fremanez
Externí odkaz:
https://doaj.org/article/62fa09b7fa36471dad994913a5d193fd
Autor:
Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen, Xiaoping Ning, Lindsay Janka, Verena Ramirez Campos, Lynda J. Krasenbaum, Dagny Holle-Lee, David Kudrow, Christian Lampl
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-4 (2022)
Externí odkaz:
https://doaj.org/article/2cfef4f751454da4afcac2578f838a35
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
Autor:
Peter McAllister, Lois Lamerato, Lynda J. Krasenbaum, Joshua M. Cohen, Krishna Tangirala, Stephen Thompson, Maurice Driessen, Julian Casciano, Zenobia Dotiwala, Alexander Mauskop
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-8 (2021)
Abstract Background Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for migraine prevention in adults. Real-world data on the effectiveness of fremanezumab are
Externí odkaz:
https://doaj.org/article/e6c3c26c5cab4ff2be1b3f2e864869c6
Autor:
Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen, Xiaoping Ning, Lindsay Janka, Verena Ramirez Campos, Lynda J. Krasenbaum, Dagny Holle-Lee, David Kudrow, Christian Lampl
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-12 (2021)
Abstract Background Although migraine is less common in older people, preventive treatment of migraine in these individuals may be more challenging due to the presence of multiple comorbidities and polypharmacy. Additionally, evidence for migraine tr
Externí odkaz:
https://doaj.org/article/85e212b2b1294997a15ab3ee23884b36
Autor:
Kimberly D. Mackenzie, Mario Ortega, Yoel Kessler, Verena Ramirez Campos, Lynda J. Krasenbaum, Karen Carr, Xiaoping Ning, Jennifer Stratton
Publikováno v:
Frontiers in Physiology, Vol 13 (2022)
Calcitonin gene-related peptide (CGRP) pathway-targeted treatments have been shown to be efficacious in the prevention of episodic and chronic migraine. Currently approved therapies include monoclonal antibodies (mAbs) that target CGRP (eptinezumab,
Externí odkaz:
https://doaj.org/article/f0c7a8dc921146898c7fe90a37c8d9e7
Autor:
Joshua M. Cohen, Xiaoping Ning, Yoel Kessler, Michele Rasamoelisolo, Verena Ramirez Campos, Michael J. Seminerio, Lynda J. Krasenbaum, Honglue Shen, Jennifer Stratton
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-8 (2021)
Abstract Background Monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway have been shown to be effective in migraine prevention. Eptinezumab, erenumab, fremanezumab, and galcanezumb have shown efficacy in clinical
Externí odkaz:
https://doaj.org/article/30df5c3385fd4b69b2d270618060643e
Autor:
George R. Nissan, Richard Kim, Joshua M. Cohen, Michael J. Seminerio, Lynda J. Krasenbaum, Karen Carr, Vincent Martin
Publikováno v:
Journal of clinical medicine. 11(15)
Migraine is a highly disabling and often chronic neurological disease that affects more than one billion people globally. Preventive migraine treatment is recommended for individuals who have frequent and/or disabling attacks; however, many of the me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::952369aaceeeaafdefb821b911fc2434
https://pubmed.ncbi.nlm.nih.gov/35955976
https://pubmed.ncbi.nlm.nih.gov/35955976
Autor:
David Kudrow, Joshua M. Cohen, Steffen Naegel, Stephanie J. Nahas, Verena Ramirez Campos, Christian Lampl, Xiaoping Ning, Lynda J. Krasenbaum, Lindsay Janka, Dagny Holle-Lee
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-12 (2021)
Background Although migraine is less common in older people, preventive treatment of migraine in these individuals may be more challenging due to the presence of multiple comorbidities and polypharmacy. Additionally, evidence for migraine treatment e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5de6d62bf16c4e80c383fd1e5150634c
https://pubmed.ncbi.nlm.nih.gov/35581545
https://pubmed.ncbi.nlm.nih.gov/35581545
Autor:
Maurice T. Driessen, Steve Barash, Joshua M. Cohen, Lynda J. Krasenbaum, Karen Carr, Xiaoping Ning, Verena Ramirez Campos
Publikováno v:
Naunyn-Schmiedeberg's Archives of Pharmacology
Recently, Gao et al. published an article titled “Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials” which concluded that monthly administration of fremanez
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d3865a97cc9d52023b895e436928fc9
https://pubmed.ncbi.nlm.nih.gov/33136176
https://pubmed.ncbi.nlm.nih.gov/33136176